Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Bajorin

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Cancer|March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2006
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatmentF C Maluf, C Cordon-Cardo, D A Verbel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2008
Detection of circulating tumor cells in patients with urothelial cancerD J Gallagher, M I Milowsky, N Ishill, et al.
Cancer Investigation|October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancerP M Dodd, J A McCaffrey, M Mazumdar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2011
Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumorsM D Galsky, L H Camacho, E G Chiorean, et al.
Cancer|November 15, 1993
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysisM N Sirott, D F Bajorin, G Y Wong, et al.
Cancer|December 1, 1993
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trialR J Motzer, E Dmitrovsky, W H Miller, et al.
British Journal of Cancer|November 1, 1996
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancerE W Steyerberg, H J Keizer, S D Fosså, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatinH Xiao, M Mazumdar, D F Bajorin, et al.
The Journal of Urology|August 1, 1996
Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancerS M Donat, H W Herr, D F Bajorin, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Cancer|March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, M Mazumdar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2006
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatmentF C Maluf, C Cordon-Cardo, D A Verbel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2008
Detection of circulating tumor cells in patients with urothelial cancerD J Gallagher, M I Milowsky, N Ishill, et al.
Cancer Investigation|October 19, 2000
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancerP M Dodd, J A McCaffrey, M Mazumdar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2011
Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumorsM D Galsky, L H Camacho, E G Chiorean, et al.
Cancer|November 15, 1993
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysisM N Sirott, D F Bajorin, G Y Wong, et al.
Cancer|December 1, 1993
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trialR J Motzer, E Dmitrovsky, W H Miller, et al.
British Journal of Cancer|November 1, 1996
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancerE W Steyerberg, H J Keizer, S D Fosså, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatinH Xiao, M Mazumdar, D F Bajorin, et al.
The Journal of Urology|August 1, 1996
Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancerS M Donat, H W Herr, D F Bajorin, et al.
Pageof 10